Understanding individual neurodegenerative progression in Parkinson’s disease through normative modelling

Parkinson's disease (PD) is a neurodegenerative disorder with motor symptoms (e.g., bradykinesia, tremors) and non-motor symptoms (e.g., cognitive deficits). Symptom progression varies across individuals, possibly due to differences in the spread of disease pathology. This study investigates individual-level gray matter atrophy in PD patients compared to a reference cohort, modeling neurobiological trajectories to understand symptom progression. Using normative modeling, we mapped individual deviations in gray matter atrophy in PD patients (Personalized Parkinson Project, PPP; N = 408; 42% female) against a reference model (N = 58, 836) of non-diagnosed individuals. Gray matter atrophy was defined as negative deviations from the normative model in cortical thickness and subcortical volume at baseline and two-year follow-up. We correlated the deviations with clinical motor and cognitive symptoms at an individual level and compared changes across PD subtypes (mild-motor predominant, intermediate, and diffuse-malignant). Cross-sectionally, PD patients showed significant gray matter atrophy, which correlated with cognitive impairment. Longitudinally, cortical thinning and subcortical atrophy patterns showed variation amongst subtypes. Specifically, the diffuse-malignant subtype, which is characterized by more diffuse symptoms and faster clinical progression, exhibited pronounced cortical thinning and subcortical atrophy over time. In this paper, we have considered the deviation scores at three levels of granularity: cases vs. control, subtypes, and the individual level. While our findings show subgroup-level patterns of variability, they also provide a method for exploring individual-level metrics of disease progression, acknowledging that individuals may deviate from the predefined categories or groups and can exhibit large variability over time.

Authors

Institutions

Publication Details

Journal
Scientific Reports
Published
2025-10-21
DOI
https://doi.org/10.1038/s41598-025-20484-x
Citations
1
Primary Topic
Parkinson's Disease Mechanisms and Treatments
Type
article
Field-Weighted Citation Impact
1.39

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Understanding individual neurodegenerative progression in Parkinson’s disease through normative modelling

Barbora Rehák Bučková, Rick C. G. Helmich, André F. Marquand, Martin E. Johansson et al.
1 citations
Scientific Reports
Parkinson's Disease Mechanisms and Treatments
1.39
article

Understanding individual neurodegenerative progression in Parkinson’s disease through normative modelling

Barbora Rehák Bučková, Rick C. G. Helmich, André F. Marquand, Martin E. Johansson, Charlotte Fraza, Christian F. Beckmann
article en
1 citations

Abstract

Parkinson's disease (PD) is a neurodegenerative disorder with motor symptoms (e.g., bradykinesia, tremors) and non-motor symptoms (e.g., cognitive deficits). Symptom progression varies across individuals, possibly due to differences in the spread of disease pathology. This study investigates individual-level gray matter atrophy in PD patients compared to a reference cohort, modeling neurobiological trajectories to understand symptom progression. Using normative modeling, we mapped individual deviations in gray matter atrophy in PD patients (Personalized Parkinson Project, PPP; N = 408; 42% female) against a reference model (N = 58, 836) of non-diagnosed individuals. Gray matter atrophy was defined as negative deviations from the normative model in cortical thickness and subcortical volume at baseline and two-year follow-up. We correlated the deviations with clinical motor and cognitive symptoms at an individual level and compared changes across PD subtypes (mild-motor predominant, intermediate, and diffuse-malignant). Cross-sectionally, PD patients showed significant gray matter atrophy, which correlated with cognitive impairment. Longitudinally, cortical thinning and subcortical atrophy patterns showed variation amongst subtypes. Specifically, the diffuse-malignant subtype, which is characterized by more diffuse symptoms and faster clinical progression, exhibited pronounced cortical thinning and subcortical atrophy over time. In this paper, we have considered the deviation scores at three levels of granularity: cases vs. control, subtypes, and the individual level. While our findings show subgroup-level patterns of variability, they also provide a method for exploring individual-level metrics of disease progression, acknowledging that individuals may deviate from the predefined categories or groups and can exhibit large variability over time.

Scientific ReportsVol. 15(1)
Radboud University Nijmegen (NL), Wellcome Centre for Human Neuroimaging (GB), King's College London (GB), Radboud University Medical Center (NL), Wellcome Centre for Integrative Neuroimaging (GB)
Wellcome Trust
Openalex Percentile: Top 15%
Parkinson's Disease Mechanisms and Treatments
1.39
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.